Edith Málaga

Edith Málaga

Auto-generated profile, based on publicly available information

Edith Málaga

Infectious Diseases Research Laboratory, Department of Cellular and Molecular Sciences, Universidad Peruana Cayetano Heredia, Lima, Peru

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JAJose C. Aponte
Jose C. Aponte
MVManuela Verástegui
Manuela Verástegui
EMEdith Málaga
Edith Málaga
MZMirko Zimic
Mirko Zimic
MQMiguel Quiliano
Miguel Quiliano
GHGerald Hammond
Gerald Hammond

19 May 2015 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
CCCarolina I Cura
Carolina I Cura
TDTomas Duffy
Tomas Duffy
RLRaúl H Lucero
Raúl H Lucero
MBMargarita Bisio
Margarita Bisio
JPJulie Péneau
Julie Péneau
ASAlejandro Schijman
Alejandro Schijman
Trypanosoma cruzi has been classified into six Discrete Typing Units (DTUs), designated as TcI–TcVI. In order to effectively use this standardized nomenclature, a reproducible genotyping strategy is imperative. Several typing schemes have been developed with variable levels of complexity, selectivity and analytical sensitivity. Most of them can be only applied to cultured stocks. In this context, we aimed to develop a multiplex Real-Time PCR method to identify the six T. cruzi DTUs using TaqMan probes (MTq-PCR). The MTq-PCR has been evaluated in 39 cultured stocks and 307 biological samples from vectors, reservoirs and patients from different geographical regions and transmission cycles in comparison with a multi-locus conventional PCR algorithm. The MTq-PCR was inclusive for laboratory stocks and natural isolates and sensitive for direct typing of different biological samples from vectors, reservoirs and patients with acute, congenital infection or Chagas reactivation. The first round SL-IR MTq-PCR detected 1 fg DNA/reaction tube of TcI, TcII and TcIII and 1 pg DNA/reaction tube of TcIV, TcV and TcVI reference strains. The MTq-PCR was able to characterize DTUs in 83% of triatomine and 96% of reservoir samples that had been typed by conventional PCR methods. Regarding clinical samples, 100% of those derived from acute infected patients, 62.5% from congenitally infected children and 50% from patients with clinical reactivation could be genotyped. Sensitivity for direct typing of blood samples from chronic Chagas disease patients (32.8% from asymptomatic and 22.2% from symptomatic patients) and mixed infections was lower than that of the conventional PCR algorithm. Typing is resolved after a single or a second round of Real-Time PCR, depending on the DTU. This format reduces carryover contamination and is amenable to quantification, automation and kit production. Chagas disease, caused by the protozoan Trypanosoma cruzi, represents a health and social threat to an estimated number of eight million people, affecting mainly neglected populations in endemic areas and emerging in non endemic countries by migratory movements. Parasite genetic diversity is related to geographical distribution and transmission cycles and might play a role in clinical manifestations as well as in anti-parasitic chemotherapy response. T. cruzi has been classified into six Discrete Typing Units (DTUs), after consensus reached among experts in the field. In order to effectively use this standardized nomenclature, a reproducible genotyping strategy is needed. Available typing schemes are usually applied to cultured parasite stocks, because they are not sensitive enough to be used in biological specimens. Only nested PCR procedures could directly type biological samples, but are prompt to contamination and require a high number of reactions. Thus, we developed a multiplex Real-Time PCR using TaqMan probes (MTq-PCR) for DTU typing in a single or a second round of amplification. It proved useful to determine DTUs in cultured stocks, vector and reservoir specimens, as well as in patients´samples, especially in those from individuals with acute, congenital infection or Chagas reactivation. It is amenable to quantification and automation for kit production.

25 March 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
Louisa Alexandra MessengerLouisa Alexandra Messenger
Louisa Alexandra Messenger
RGRobert H. Gilman
Robert H. Gilman
MVManuela Verastegui
Manuela Verastegui
GGGerson Galdos-Cardenas
Gerson Galdos-Cardenas
GSGerardo Sanchez
Gerardo Sanchez
FPfor the Working Group on Chagas Disease in Bolivia and Peru
for the Working Group on Chagas Disease in Bolivia and Peru
Congenital Trypanosoma cruzi transmission is now estimated to account for 22% of new infections, representing a significant public health problem across Latin America and internationally. Treatment during infancy is highly efficacious and well tolerated, but current assays for early detection fail to detect >50% of infected neonates, and 9-month follow-up is low. Women who presented for delivery at 2 urban hospitals in Santa Cruz Department, Bolivia, were screened by rapid test. Specimens from infants of infected women were tested by microscopy (micromethod), quantitative PCR (qPCR), and immunoglobulin (Ig)M trypomastigote excreted-secreted antigen (TESA)-blots at birth and 1 month and by IgG serology at 6 and 9 months. Among 487 infants of 476 seropositive women, congenital T. cruzi infection was detected in 38 infants of 35 mothers (7.8%). In cord blood, qPCR, TESA-blot, and micromethod sensitivities/specificities were 68.6%/99.1%, 58.3%/99.1%, and 16.7%/100%, respectively. When birth and 1-month results were combined, cumulative sensitivities reached 84.2%, 73.7%, and 34.2%, respectively. Low birthweight and/or respiratory distress were reported in 11 (29%) infected infants. Infants with clinical signs had higher parasite loads and were significantly more likely to be detected by micromethod. The proportion of T. cruzi–infected infants with clinical signs has fallen since the 1990s, but symptomatic congenital Chagas disease still represents a significant, albeit challenging to detect, public health problem. Molecular methods could facilitate earlier diagnosis and circumvent loss to follow-up but remain logistically and economically prohibitive for routine screening in resource-limited settings.

1 October 2014 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
VSVishal Shah
Vishal Shah
LFLisbeth Ferrufino
Lisbeth Ferrufino
RGRobert H. Gilman
Robert H. Gilman
MRMargot Ramirez
Margot Ramirez
ESEliana Saenza
Eliana Saenza
CBCaryn Bern
Caryn Bern
Trypanosoma cruzicauses Chagas disease, which affects an estimated 7 million to 8 million people. Chagas disease is endemic throughout Latin America, with the highest prevalence in Bolivia. Conventional diagnosis requires a well-equipped laboratory with experienced personnel. We evaluated the Chagas Detect Plus (CDP) (InBios, Seattle, WA), a rapid immunochromatographic assay for IgG antibodies toT. cruzi. CDP performance was compared to infection status based on results obtained by indirect hemagglutination assay, immunofluorescent-antibody test, and enzyme-linked immunosorbent assay. Confirmed infection required positive results by at least 2 conventional assays. We used specimens from adults of both sexes in a general hospital in the city of Santa Cruz and from pregnant women in a hospital and children in villages in the Bolivian Chaco, an area of hyperendemicity. CDP was performed in paired whole-blood and serum specimens from 385 individuals in the two hospital studies and in 200 serum specimens from the community study. CDP showed sensitivities/specificities of 96.2% (95% confidence interval, 92.7 to 98.4)/98.8% (95.9 to 99.9) in whole blood and 99.3% (97.5 to 99.9)/96.9% (94.2 to 98.6) in serum, with no differences by sex, age group, or study site. CDP showed excellent sensitivity and specificity in our study population, comparable to those of conventional serology. The test is reliable for field surveys, requires no laboratory equipment, and performed well in serum and whole blood. The CDP could also be used for accurate maternal screening to identify neonates at risk of congenital transmission. CDP performance data in diverse geographic areas are needed to strengthen the evidence base for its use.

1 April 2011 in Experimental Parasitology
Verified
Journal Article
Closed access
YEYannick Estevez
Yannick Estevez
MQMiguel Quiliano
Miguel Quiliano
ABAsunción Burguete
Asunción Burguete
BCBilly Cabanillas
Billy Cabanillas
MZMirko Zimic
Mirko Zimic
EDEric Deharo
Eric Deharo

1 April 2010 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
JAJose C. Aponte
Jose C. Aponte
AVAbraham Vaisberg
Abraham Vaisberg
DCDenis Castillo
Denis Castillo
GGGerman Gonzalez
German Gonzalez
YEYannick Estevez
Yannick Estevez
GHGerald B. Hammond
Gerald B. Hammond